-
2024 Dr. Hubert van Tol Travel Fellowship Q
https://braincanada.ca/fr/subventions-financées/2024-dr-hubert-van-tol-travel-fellowship-q2024 Dr. Hubert van Tol Travel Fellowship Vincent Bazinet, a Doctoral student at McGill University, aims to develop standardized workflows for high-resolution 7T MRI to provide clearer and more detailed insights into brain structure and function. Project Overview Vincent Bazinet, a Doctoral...
-
4,67 millions de dollars pour répondre à des questions scientifiques et créer des liens internationaux au sein de la communauté des chercheurs
https://braincanada.ca/fr/à-propos-de/nouvelles-mises-à-jour/4-67-millions-d-euros-pour-aider-à-répondre-aux-questions-scientifiques-et-créer-des-liens-internationaux-au-sein-de-la-communauté-des-chercheursBrain Canada est heureux d'annoncer l'octroi d'une subvention de soutien à la plateforme (PSG) de 4 674 000 $ en 2019 au Dr Julien Doyon et à son équipe pour le Centre d'imagerie cérébrale McConnell (CIC) de l'Institut neurologique de Montréal (le Neuro). Ce financement soutiendra une plateforme...
-
6 millions de dollars pour la recherche sur la démence
https://braincanada.ca/fr/à-propos-de/nouvelles-mises-à-jour/6-millions-d-euros-pour-la-recherche-sur-la-démenceLa Fondation Brain Canada, en partenariat avec la Société Alzheimer du Canada, l'Institut du vieillissement des Instituts de recherche en santé du Canada et Research Manitoba, investit 5 989 000 $ dans 44 chercheurs sur les démences dans le cadre du concours annuel de recherche de la Société...
-
7,7 M$ pour la science ouverte et l'innovation en santé cérébrale
https://braincanada.ca/fr/à-propos-de/nouvelles-mises-à-jour/plateformes-de-santé-cérébrale-pilotées-par-l-intelligence-artificielleDeux plateformes de pointe à CAMH et à l’Université Western accéléreront la recherche sur le cerveau grâce à l’IA et au partage mondial des données. De gauche à droite : Aristotle Voineskos (CAMH), Sarah Downey (CAMH), Viviane Poupon (Brain Canada), Tristan Glatard (CAMH) et Ali Khan (Western), à...
-
[99m]Technetium-based radioligands for improving access to state-of-the-art molecular imaging of neurodegeneration
https://braincanada.ca/fr/subventions-financées/99m-technetium-based-radioligands-for-improving-access-to-state-of-the-art-molecular-imaging-of-neurodegenerationMedical imaging has changed how we study and treat brain degeneration. Project Overview Medical imaging has changed how we study and treat brain degeneration. The best tool for imaging subtle changes to brain proteins is positron emission tomography (or PET). But that has limited availability. An...
-
A brain-specific approach to RNA therapeutics: developing a novel protein delivery strategy for the central nervous system
https://braincanada.ca/fr/subventions-financées/a-brain-specific-approach-to-rna-therapeutics-developing-a-novel-protein-delivery-strategy-for-the-central-nervous-systemChallenge: Delivery of therapeutic proteins to the brain has been a longstanding barrier to CNS drug development. Project Overview Challenge: Delivery of therapeutic proteins to the brain has been a longstanding barrier to CNS drug development. Protein replacement or supplementation strategies hold...
-
A combined in-vivo ex-vivo approach to investigate imaging biomarkers in ALS diagnosis and aetiology
https://braincanada.ca/fr/subventions-financées/a-combined-in-vivo-ex-vivo-approach-to-investigate-imaging-biomarkers-in-als-diagnosis-and-aetiologyAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure, leading to progressive loss of motor function and ultimately death. Project Overview Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure, leading to progressive loss of motor...
-
A critical examination of family caregivers’ views on and experiences with medical assistance in dying
https://braincanada.ca/fr/subventions-financées/a-critical-examination-of-family-caregivers-views-on-and-experiences-with-medical-assistance-in-dyingIndividuals with an incurable condition marked by decline and intolerable suffering and where death is reasonably foreseeable, as with dementia, now have access to medical assistance in dying (MAID). Project Overview Individuals with an incurable condition marked by decline and intolerable...
-
A Drug Screening Assay to Reduce LINGO-1 Amounts in Neurons
https://braincanada.ca/fr/subventions-financées/a-drug-screening-assay-to-reduce-lingo-1-amounts-in-neuronsThe LINGO-1 protein is strongly associated with Alzheimer’s disease and is a novel drug target. Project Overview The LINGO-1 protein is strongly associated with Alzheimer’s disease and is a novel drug target. LINGO-1 is a transmembrane protein that negatively regulates neuronal survival and...
-
A Drug Screening Platform to Increase Protein Expression Levels for Treatment of Neurological Disorders
https://braincanada.ca/fr/subventions-financées/a-drug-screening-platform-to-increase-protein-expression-levels-for-treatment-of-neurological-disordersNeurological and psychiatric diseases and disorders affect more than half the population. Project Overview Neurological and psychiatric diseases and disorders affect more than half the population. These disorders of the nervous system can span a range of illnesses, including generalized anxiety...
Passer au contenu principal
